868540-15-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzyl ((S)-2-((tert-butoxycarbonyl)aMino)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate is used as a reagent for the preparation of peptides that inhibit enzymes. This application is particularly relevant in the development of drugs targeting specific enzymes involved in various diseases, such as inflammation, cancer, and metabolic disorders.
Used in Peptide Synthesis:
In the field of peptide synthesis, benzyl ((S)-2-((tert-butoxycarbonyl)aMino)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate plays a crucial role as a building block for the assembly of larger peptide structures. Its unique structure allows for the formation of specific peptide bonds, which can be further modified or functionalized to create bioactive molecules with therapeutic potential.
Used in Enzyme Inhibition Research:
Benzyl ((S)-2-((tert-butoxycarbonyl)aMino)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate is also used in research settings to study enzyme inhibition mechanisms. By incorporating benzyl ((S)-2-((tert-butoxycarbonyl)aMino)-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate into peptide sequences, scientists can investigate the interactions between peptides and their target enzymes, leading to a better understanding of enzyme function and the development of more effective enzyme inhibitors.

Upstream product

• 70637-28-4 (S)-benzyl 2-((S)-2-amino-4-methylpentanamido)-3-phenylpropanoate TFA salt 
• 82732-07-8 Boc-L-homophenylalanine 
• 140834-91-9 (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate 
• 2462-32-0 L-phenylalanine benzyl ester hydrochloride 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 

Downstream Products

• 868540-17-4 carfilzomib 
• 875309-92-5 (S)-benzyl 2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamido)-3-phenylpropanoate 
• 868540-16-3 (S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenyipropanoic acid 
• 875309-83-4 C₂HF₃O₂*C₃₂H₃₉N₃O₄ 

Relevant academic research and scientific papers

Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy to Overcome Cancer Resistance to Carfilzomib and Bortezomib

Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined. The lack of a clear understanding of clinical PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies. Here, we designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1′ site. We show that a Cfz analog, 9, harboring a hydroxyl substituent at its P1′ position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz. These results suggest that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to bypass resistance mechanisms associated with Cfz and to provide additional clinical options for patients resistant to Cfz.

AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.

Compounds for enzyme inhibition

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.